Document 0137
 DOCN  M9590137
 TI    Treatment of pulmonary disease caused by Mycobacterium kansasii: results
       of 18 vs 12 months' chemotherapy.
 DT    9509
 AU    Sauret J; Hernandez-Flix S; Castro E; Hernandez L; Ausina V; Coll P;
       Departamento Neumologia, Hospital de Sant Pau, Barcelona, Spain.
 SO    Tuber Lung Dis. 1995 Apr;76(2):104-8. Unique Identifier : AIDSLINE
       MED/95299084
 AB    SETTING: Chest Clinic, Sant Pau Hospital, Barcelona, Spain. OBJECTIVE:
       To assess the therapeutic response of pulmonary disease due to
       Mycobacterium kansasii to 12 and 18 months of chemotherapy. DESIGN: 28
       patients with criteria of pulmonary disease caused by M. kansasii not
       associated with HIV-infection were identified in our department in the
       period 1985-91 (24 male, 4 female, mean age 56 +/- 12 years). 14
       patients were treated with rifampicin-isoniazid-ethambutol daily for 12
       months (ethambutol only for the first 6 months), and 14 with the same
       regimen for 18 months. The follow-up after treatment was 12-30 months.
       RESULTS: All patients showed improvement of radiographic manifestation
       of disease and sputum conversion (mean time: 4.5 +/- 2 months). The
       adverse drug effects were minimal. No failures were detected, and only
       one patient (3.5%), in the group of 12-month chemotherapy, relapsed
       after finishing the treatment. CONCLUSIONS: Our findings suggest that
       pulmonary disease due to M. kansasii has an effective response to
       12-month chemotherapy regimen and that it is not necessary to prolong
       the administration of ethambutol for more than 6 months.
 DE    Adult  Aged  Aged, 80 and over  Antitubercular Agents/*ADMINISTRATION &
       DOSAGE  Comparative Study  Ethambutol/ADMINISTRATION & DOSAGE  Female
       Human  Isoniazid/ADMINISTRATION & DOSAGE  Male  Middle Age
       Mycobacterium Infections, Atypical/*DRUG THERAPY  Prospective Studies
       Rifampin/ADMINISTRATION & DOSAGE  Time Factors  Tuberculosis,
       Pulmonary/*DRUG THERAPY  CLINICAL TRIAL  JOURNAL ARTICLE  RANDOMIZED
       CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).